Ruopeng Zha

1.5k total citations
17 papers, 1.2k citations indexed

About

Ruopeng Zha is a scholar working on Molecular Biology, Cancer Research and Pharmacology. According to data from OpenAlex, Ruopeng Zha has authored 17 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Cancer Research and 2 papers in Pharmacology. Recurrent topics in Ruopeng Zha's work include MicroRNA in disease regulation (10 papers), RNA modifications and cancer (6 papers) and Cancer-related molecular mechanisms research (6 papers). Ruopeng Zha is often cited by papers focused on MicroRNA in disease regulation (10 papers), RNA modifications and cancer (6 papers) and Cancer-related molecular mechanisms research (6 papers). Ruopeng Zha collaborates with scholars based in China and Taiwan. Ruopeng Zha's co-authors include Xianghuo He, Shenglin Huang, Linhui Liang, Qi Tian, Yingjun Zhao, Weijie Guo, Jinjun Li, Taoyang Chen, Qifeng Wang and Jie Ding and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Ruopeng Zha

17 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruopeng Zha China 16 938 831 111 93 79 17 1.2k
Changzheng Liu China 16 882 0.9× 782 0.9× 113 1.0× 68 0.7× 133 1.7× 33 1.3k
Tao Song China 19 699 0.7× 534 0.6× 62 0.6× 102 1.1× 44 0.6× 40 969
Chaoxia Zou China 16 673 0.7× 520 0.6× 49 0.4× 66 0.7× 91 1.2× 35 926
Lifeng Liu China 18 708 0.8× 323 0.4× 55 0.5× 87 0.9× 74 0.9× 46 965
Salvatore Delogu Germany 6 552 0.6× 384 0.5× 114 1.0× 60 0.6× 152 1.9× 6 846
Runping Fang China 18 733 0.8× 403 0.5× 57 0.5× 82 0.9× 105 1.3× 26 943
Zhangqian Chen China 14 700 0.7× 421 0.5× 78 0.7× 107 1.2× 50 0.6× 19 961
Longcheng Shang China 15 562 0.6× 376 0.5× 89 0.8× 115 1.2× 172 2.2× 21 961
Sandra Mattu Italy 7 487 0.5× 359 0.4× 112 1.0× 50 0.5× 151 1.9× 8 800

Countries citing papers authored by Ruopeng Zha

Since Specialization
Citations

This map shows the geographic impact of Ruopeng Zha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruopeng Zha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruopeng Zha more than expected).

Fields of papers citing papers by Ruopeng Zha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruopeng Zha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruopeng Zha. The network helps show where Ruopeng Zha may publish in the future.

Co-authorship network of co-authors of Ruopeng Zha

This figure shows the co-authorship network connecting the top 25 collaborators of Ruopeng Zha. A scholar is included among the top collaborators of Ruopeng Zha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruopeng Zha. Ruopeng Zha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Zha, Ruopeng, Weijie Guo, Zhenfeng Zhang, et al.. (2014). Genome-Wide Screening Identified That miR-134 Acts as a Metastasis Suppressor by Targeting Integrin β1 in Hepatocellular Carcinoma. PLoS ONE. 9(2). e87665–e87665. 62 indexed citations
2.
Pang, Fei, Ruopeng Zha, Yingjun Zhao, et al.. (2014). MiR-525-3p Enhances the Migration and Invasion of Liver Cancer Cells by Downregulating ZNF395. PLoS ONE. 9(3). e90867–e90867. 32 indexed citations
3.
Guo, Weijie, Yingjun Zhao, Yifei Wang, et al.. (2014). MicroRNA‐135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer Science. 105(8). 956–965. 62 indexed citations
4.
Guo, Weijie, Yingjun Zhao, Yifei Wang, et al.. (2014). MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. International Journal of Oncology. 44(6). 2050–2058. 51 indexed citations
5.
Wang, Qifeng, Zhaohui Huang, Weijie Guo, et al.. (2013). MicroRNA-202-3p Inhibits Cell Proliferation by Targeting ADP-Ribosylation Factor-like 5A in Human Colorectal Carcinoma. Clinical Cancer Research. 20(5). 1146–1157. 63 indexed citations
6.
Ding, Jie, Shenglin Huang, Ying Wang, et al.. (2013). Genome-Wide Screening Reveals That miR-195 Targets the TNF-α/NF-κB Pathway by Down-Regulating IΚB Kinase Alpha and TAB3 in Hepatocellular Carcinoma. Hepatology. 58(2). 654–666. 114 indexed citations
7.
Tian, Qi, Linhui Liang, Jie Ding, et al.. (2012). MicroRNA-550a Acts as a Pro-Metastatic Gene and Directly Targets Cytoplasmic Polyadenylation Element-Binding Protein 4 in Hepatocellular Carcinoma. PLoS ONE. 7(11). e48958–e48958. 48 indexed citations
8.
Chen, Zhiao, et al.. (2012). Suppression of Human Liver Cancer Cell Migration and Invasion via the GABAA Receptor.. SHILAP Revista de lepidopterología. 9(2). 90–8. 17 indexed citations
9.
Zheng, Biqiang, Linhui Liang, Chunmeng Wang, et al.. (2011). MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer. Clinical Cancer Research. 17(24). 7574–7583. 230 indexed citations
10.
Lin, Jun, Shenglin Huang, Shun‐Quan Wu, et al.. (2011). MicroRNA-423 promotes cell growth and regulates G 1 /S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis. 32(11). 1641–1647. 104 indexed citations
11.
Jia, Deshui, Lin Wei, Weijie Guo, et al.. (2011). Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology. 54(4). 1227–1236. 103 indexed citations
12.
Chen, Zhiao, Yongfen Xu, Yingjun Zhao, et al.. (2011). Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver International. 32(2). 331–338. 91 indexed citations
13.
Qiao, Ying, Linhui Liang, Weijie Guo, et al.. (2010). Hypoxia-inducible MicroRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 54(6). 2064–2075. 151 indexed citations
14.
Zhang, Haifei, et al.. (2010). Magnesium lithospermate B decreases [Ca2+]i in endothelial cells by inhibiting K+ currents. European Journal of Pharmacology. 650(1). 285–289. 5 indexed citations
15.
Wang, Wenyi, Jie Li, Yang Ding, et al.. (2009). OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovascular Research. 85(4). 845–852. 60 indexed citations
16.
Xu, Wei, Ruopeng Zha, Wenyi Wang, & Yiping Wang. (2007). Effects of scutellarin on PKC? in PC12 cell injury induced by oxygen and glucose deprivation. Acta Pharmacologica Sinica. 28(10). 1573–1579. 28 indexed citations
17.
Zha, Ruopeng, Wei Xu, Wenyi Wang, Dong Li, & Yiping Wang. (2007). Prevention of lipopolysaccharide-induced injury by 3,5-dicaffeoylquinic acid in endothelial cells. Acta Pharmacologica Sinica. 28(8). 1143–1148. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026